Long COVID Kids DK - Investigating Long-term Covid-19

NCT ID: NCT04786353

Last Updated: 2024-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

330000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-01

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

During the COVID-19 pandemic children have been perceived as a group not being especially affected, with less being infected, low symptom burden and low mortality. A small proportion however develop life-threatening hyperinflammation (mis-c) and at least one Danish child has died from this condition. Since the fall of 2020 international awareness has been raised by parents reporting that their children experience gastrointestinal issues, chest pain, headaches, fatigue, joint/muscle pain, sore throat, dizziness, nausea and fever for months following COVID-19 infection.

In this study the investigators aim to investigate the proportions of possible long covid in the 45.000 Danish children that has been tested positive for covid-19. The investigators know from the Danish Covid-19 surveillance data that 300 has been admitted to the hospital within the first 2 weeks after diagnosing. However, no knowledge about how many visits the participants have to the ER and GP compared to children without covid-19 as well as hospital admissions within the first year and medical prescriptions within the first year. This knowledge can give the investigators an indication of how affected these children are on the long term. Furthermore, data has been collected about the long-term symptoms in adults, but not children, and it now seems obvious that this data are needed to fully understand the disease and orchestra the relevant medical attention for children during the covid-19 pandemic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives

WP 1 Objective: to investigate long COVID symptoms after 3,6,9 and 12 months in children tested positive for SARS-CoV-2 compared to children without a positive test.

WP 2 Objective: to describe whether there is a difference in the number of visits to general practitioner, emergency department and hospitalizations in children with and without SARS-CoV-2. In addition, which co-morbid diagnoses are given 3,6,9 and 12 months after diagnosis with COVID and which drugs are prescribed.

Methods

Design: National register study and questionnaire survey.

Outcomes

WP1: Long-term COVID-19 symptoms in children will be identified from questionnaires.

WP2: To determine the difference in number of contacts to the general practitioner, emergency departments and hospitalizations in both children with and without SARS-CoV-2, an identification from COVID-19 data linked with LPR3 and SSR will occur. Identification of co-morbidities will be identified from LPR3 and prescribed drugs are available from LMDB.

Statistical analyses

WP1: To investigate parent and child reported long COVID symptoms numbers and percentages will be presented followed by multiple logistic models offered as odds ratios (OR) with 95% confidence intervals (CI).

WP2: Multiple regressions models presented as OR with 95% CI will be used to examine the differences in contacts regarding the general practitioner, emergency departments, hospitalizations, co-morbidities and prescribed drugs in children with and without COVID.

All analyses will be stratified by age groups and gender.

Population

Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires the investigators will also need CPR-data on the children's parents.

Non-exposure: Children from 0-18 years without a positive SARS-CoV-2 test for the entire period of January 2020 until the last updated version will be identified from the Danish Civil Registration System. To be able to identify the parents who will receive the questionnaires the investigators will need CPR-data on the parents.

Variables

COVID-19 data will enable information on children with and without positive SARS-CoV-2 tests. The parents who will receive questionnaires will also be identified from this register likewise will data on death, sex and age.

The Temporary Danish National Patient Register (LPR3) will provide data on the number of emergency visits, hospitalizations and co-morbidities.

The Danish Health Insurance Register (SSR) offers numbers of contacts with the general practitioner.

The Danish Medicines Registry (LMDB) enables the investigators to link prescribed drugs.

All registers will be updated monthly by The Danish Health Authorities and the investigators will need data extraction in the period 2020 until the last updated version from all the above-mentioned registers.

Publications of results

All results will be published in international scientist journals as well as the hospital webpage and press releases.

Perspectives

This will be the largest investigation of long COVID in children to date. Denmark has excellent registers and logistics for questionnaires providing a unique opportunity to report on children's health care seeking behavior and symptoms after being infected with COVID-19. Children are an overlooked group during the pandemic and these data will provide essential information for health care staff, politicians and parents.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COVID positive kids

Children with at least one positive SARS-CoV-2 test.

LongCOVIDkidsDK

Intervention Type OTHER

Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.

Controls

Children with no positive SARS-CoV-2 test.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LongCOVIDkidsDK

Exposure: To be identified as an exposure for the current study, children from 0-18 years with at least one positive SARS-CoV-2 test will be identified from COVID-19 data from January 2020 until the last updated version. To be able to identify the parents who will receive the questionnaires we will also need CPR-data on the children's parents.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* must be included in the covid-19 monitoring database

Exclusion Criteria

\-
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rigshospitalet, Denmark

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Selina Kikkenborg Berg

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Selina K Berg, PhD

Role: PRINCIPAL_INVESTIGATOR

29190623

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet, Copenhagen University Hospital

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Bering L, Christensen AV, Birk NM, Thygesen LC, Bundgaard H, Benfield T, Nygaard U, Johannesen J, Nielsen SD, Berg SK. Risk of New-onset Type 1 Diabetes in Danish Children and Adolescents After SARS-CoV-2 Infection: A Nationwide, Matched Cohort Study. Pediatr Infect Dis J. 2023 Nov 1;42(11):999-1001. doi: 10.1097/INF.0000000000004063. Epub 2023 Aug 3.

Reference Type DERIVED
PMID: 37566892 (View on PubMed)

Kikkenborg Berg S, Palm P, Nygaard U, Bundgaard H, Petersen MNS, Rosenkilde S, Thorsted AB, Ersboll AK, Thygesen LC, Nielsen SD, Vinggaard Christensen A. Long COVID symptoms in SARS-CoV-2-positive children aged 0-14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health. 2022 Sep;6(9):614-623. doi: 10.1016/S2352-4642(22)00154-7. Epub 2022 Jun 23.

Reference Type DERIVED
PMID: 35752194 (View on PubMed)

Kikkenborg Berg S, Dam Nielsen S, Nygaard U, Bundgaard H, Palm P, Rotvig C, Vinggaard Christensen A. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): a national, cross-sectional study. Lancet Child Adolesc Health. 2022 Apr;6(4):240-248. doi: 10.1016/S2352-4642(22)00004-9. Epub 2022 Feb 8.

Reference Type DERIVED
PMID: 35143771 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Long COVID-19 Kids DK

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Motility Mother-Child Cohort
NCT05491161 ACTIVE_NOT_RECRUITING
Vitamin B12, Neurodevelopment and Growth in Nepal
NCT02272842 UNKNOWN PHASE2/PHASE3